You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

LOXL-2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Targeting LOXL2 and Cardiac Fibrosis for Post-acute Heart

Recruiting
  • Heart Failure; With Decompensation
  • exercise based cardiac rehabilitation
  • Kaohsiung, Taiwan
    Chang Gung Memorial Hospital Heart Failure Center
Aug 16, 2022

Myelofibrosis Trial in Worldwide (GB2064)

Recruiting
  • Myelofibrosis
  • Houston, Texas
  • +11 more
Nov 23, 2022

Liver Fibrosis, Hepatitis C, HIV Trial run by the (Simtuzumab)

Completed
Has Results
  • Liver Fibrosis
  • +3 more
  • Simtuzumab
  • Bethesda, Maryland
    NIH Department of Laboratory Medicine
Oct 22, 2019

Benefits of Multi-discipline Disease Management Program in Heart

Recruiting
  • Heart Failure With Decompensation
  • multi-discipline disease management program
  • Kaohsiung, Bird Pine Area, Taiwan
    Chang Gung Memorial Hospital Heart Failure Center
Mar 8, 2022

Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary

Withdrawn
  • Myelofibrosis Transformation in Essential Thrombocythemia
  • +2 more
  • LOXL2 Inhibitor PAT-1251
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2019

Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Residual Disease
  • (no location specified)
Nov 15, 2023

Hepatocellular Carcinoma, Cancer of Liver Trial (PXS-5505 and Atezolizumab and Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Cancer of Liver
  • PXS-5505 and Atezolizumab and Bevacizumab
  • Rochester, New York
    University of Rochester
Nov 3, 2022

Pharmacokinetics Trial in Adelaide (PXS-5382A)

Completed
  • Pharmacokinetics
  • Adelaide, Australia
    CMAX
Jun 24, 2020

Primary Sclerosing Cholangitis (PSC) Trial in Worldwide (Simtuzumab, Placebo)

Completed
Has Results
  • Primary Sclerosing Cholangitis (PSC)
  • Simtuzumab
  • Placebo
  • Phoenix, Arizona
  • +74 more
Oct 3, 2019

Idiopathic Pulmonary Fibrosis Trial in San Francisco, Boston, New York (EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone,

Not yet recruiting
  • Idiopathic Pulmonary Fibrosis
  • EGCG + Nintedanib
  • +2 more
  • San Francisco, California
    UCSF Parnassus
Apr 25, 2022

Hepatitis C Virus Infection Trial in Taiwan (LDV/SOF)

Completed
Has Results
  • Hepatitis C Virus Infection
  • Changhua, Taiwan
  • +10 more
Feb 18, 2020

Liver Fibrosis Due to NASH Trial in Worldwide (Placebo, SIM)

Terminated
Has Results
  • Liver Fibrosis Due to NASH
  • Placebo
  • SIM
  • Phoenix, Arizona
  • +58 more
Mar 1, 2019

Liver Fibrosis Due to NASH Trial in Worldwide (Placebo, SIM)

Terminated
Has Results
  • Liver Fibrosis Due to NASH
  • Placebo
  • SIM
  • Phoenix, Arizona
  • +67 more
Mar 1, 2019

Duchenne Muscular Dystrophy Trial in Portland (NS-089/NCNP-02)

Not yet recruiting
  • Duchenne Muscular Dystrophy
  • Portland, Oregon
    Shriners Hospital for Children
Aug 16, 2023

Respiratory Viral Infection, SARS CoV 2 Infection Trial in Banjul

Active, not recruiting
  • Respiratory Viral Infection
  • SARS CoV 2 Infection
    • Banjul, Western Region, Gambia
      Field study in the West Coast Region and Kanifing Municipality C
    Jul 11, 2023

    Colonoscopy Trial in Nanjing (after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed

    Recruiting
    • Colonoscopy
    • after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours
    • Nanjing, Jiangsu, China
      Nanjing First Hospital
    Oct 26, 2023

    Food Effect in Healthy Participants Trial in Geelong, Melbourne (ORIC-114)

    Not yet recruiting
    • Food Effect in Healthy Participants
    • Geelong, Victoria, Australia
    • +1 more
    Aug 22, 2023

    COVID-19 Trial in United States (XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose))

    Not yet recruiting
    • COVID-19
    • XBB.1.5 Vaccine (Booster)
    • XBB.1.5 Vaccine (single dose)
    • Mobile, Alabama
    • +29 more
    Aug 4, 2023

    COVID-19 Trial in Thái Bình (COVIVAC vaccine)

    Completed
    • COVID-19
    • COVIVAC vaccine
    • Thái Bình, Thai Binh, Vietnam
      District Health Center of Vu Thu District
    Jul 12, 2023

    Prodromal Alzheimer's Disease, Alzheimer, Mild Cognitive Impairment Trial in Solna (LCHF, HCLF)

    Recruiting
    • Prodromal Alzheimer's Disease
    • +3 more
    • LCHF
    • HCLF
    • Solna, Sweden
      Karolinska University Hospital
    Oct 23, 2023

    Visual Acuity Trial in Jacksonville, Saint Augustine (Blink® Tears eye drops, Investigational lipid eye drops)

    Completed
    • Visual Acuity
    • Blink® Tears eye drops
    • Investigational lipid eye drops
    • Jacksonville, Florida
    • +1 more
    Nov 9, 2023

    SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac

    Recruiting
    • Coronary Artery Disease
    • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
    • Shah Alam, Selangor, Malaysia
      Institute for Clinical Research, National Institutes of Health,
    Nov 9, 2023

    Fatty Liver, Nonalcoholic Trial (SGLT2 inhibitor)

    Not yet recruiting
    • Fatty Liver, Nonalcoholic
    • SGLT2 inhibitor
    • (no location specified)
    Oct 31, 2023

    COVID-19 Vaccine, COVID-19 Trial in Bangkok (50 µg Baiya SARS-CoV-2 Vax 2, Placebo)

    Not yet recruiting
    • COVID-19 Vaccine
    • COVID-19
    • 50 μg Baiya SARS-CoV-2 Vax 2
    • Placebo
    • Bangkok, Thailand
      Queen Saovabha Memorial Institute
    May 23, 2023

    Alcohol Use Disorder Trial (Prazosin + cyproheptadine, KT110)

    Not yet recruiting
    • Alcohol Use Disorder
    • Prazosin + cyproheptadine
    • KT110
    • (no location specified)
    Nov 27, 2023